FOLFIRI plus panitumumab can lead to an increased PFS in colorectal cancer patients

Share :
Published: 20 Apr 2010
Views: 9679
Dr Thierry Andre - Hopital Tenon, Paris, France
A study comparing FOLFIRI regimens with FOLFIRI plus panitumumab showed a two month increase in progression free survival among the patients with wild type KRAS treated with FOLFIRI plus panitumumab. Side effects are limited and manageable but include discomfort in the skin around the hands and feet and diarrhea.